
Exelixis (($EXEL)) has held its Q3 earnings call. Read on for the main highlights of the call. The Exelixis earnings call carried a strongly positive tone, supported by solid revenue,
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| EXEL | Exelixis | 68.26 | 27.06 | 65.67% |
| Name | Price | % Change | |
|---|---|---|---|
| $68.26 | +65.67% |

Exelixis (($EXEL)) has held its Q3 earnings call. Read on for the main highlights of the call. The Exelixis earnings call carried a strongly positive tone, supported by solid revenue,

Morgan Stanley lowered the firm’s price target on Exelixis (EXEL) to $57 from $60 and keeps an Equal Weight rating on the shares. The firm adjusted estimates and targets among

H.C. Wainwright raised the firm’s price target on Exelixis (EXEL) to $78 from $56 and keeps a Buy rating on the shares post the Q3 report. The firm says Exelixis

Morgan Stanley raised the firm’s price target on Exelixis (EXEL) to $60 from $53 and keeps an Equal Weight rating on the shares. Published first on TheFly – the ultimate

Truist analyst Gregory Renza raised the firm’s price target on Exelixis (EXEL) to $60 from $54 and keeps a Hold rating on the shares. The company reported Q3 EPS with

TD Cowen raised the firm’s price target on Exelixis (EXEL) to $76 from $55 and keeps a Buy rating on the shares. The firm said Q3 cabo franchise sales of

Barclays raised the firm’s price target on Exelixis (EXEL) to $54 from $49 and keeps an Equal Weight rating on the shares. Published first on TheFly – the ultimate source

Reports Q3 revenue $658.7M, consensus $646.51M. “Exelixis (EXEL) continued to execute across all of our key priorities in the third quarter, driving the cabozantinib franchise forward while preparing for zanzalintinib

16:37 EDT Exelixis (EXEL) sees FY26 revenue $2.5B-$2.55B, consensus $2.55B Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks

Bristol-Myers Squibb Company ($BMY), Exelixis ($EXEL) announced an update on their ongoing clinical study. The long term extension study NCT07620574 backed by Exelixis and Bristol Myers Squibb lets cancer patients
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| hold | Assigned | Nov 13, 2026 | ||||
| hold | Reiterated | Nov 9, 2026 | ||||
| hold | Reiterated | Nov 5, 2026 | ||||
| buy | Reiterated | Nov 2, 2026 | ||||
| buy | Reiterated | Oct 30, 2026 | ||||
| hold | Reiterated | Oct 30, 2026 | ||||
| hold | Reiterated | Oct 30, 2026 | ||||
| hold | Assigned | Oct 30, 2026 | ||||
| hold | Reiterated | Oct 30, 2026 | ||||
| buy | Reiterated | Oct 19, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 9, 2027TBA | $16.84B | $1.00 | $659.70M | 0.25 | 20.00 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.